This is the authors' abstract. We don't add key points for this paper.
The legacy of male bias within pharmaceutical research, regulation, and commercialisation needs to be rectified, argue Sundari Ravindran and colleagues
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ravindran et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: